1
|
Sibagatova A, Benberin V, Akhmetova K, Babenko D, Karabayeva R. Association of Polymorphism rs2736990 of the α-Synuclein Gene with Metabolic Syndrome Among the Population of Kazakhstan with Arterial Hypertension. Metab Syndr Relat Disord 2024; 22:263-268. [PMID: 38377606 DOI: 10.1089/met.2023.0222] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/22/2024] Open
Abstract
Background: The prevalence of metabolic syndrome (MetS) in Kazakhstan reaches 40%. The presence of an association between certain genetic markers and the development of MetS will allow more accurately determining the cardiovascular risk for patients with hypertension and personalizing preventive recommendations. Methods: The purpose of the study was to investigate the presence of an associative relationship between various polymorphisms of the α-synuclein gene and the development of MetS in Kazakh people with high blood pressure. Four hundred twenty-six patients were examined [age 49.5 (interquartile range 42.5-56), men 209 (49.1%), women 217 (50.9%)]. Standard clinical and laboratory methods were used. AutoMate Express™ and OpenArray technologies were used for DNA extraction and further genotyping. Patients with MetS made up the ms+ group, those without MetS-the ms- group. Results: In the examined patients, four polymorphisms of the α-synuclein gene were identified: rs356219, rs2736990, rs11931074, and rs2737029. According to the results of statistical analysis, the frequency and risk of developing MetS did not depend on different alleles and inheritance types of polymorphisms rs356219 and rs11931074. The minor allele of polymorphism rs2737029 exhibits a higher frequency in patients with arterial hypertension accompanied by MetS, although the specific model of inheritance remains to be conclusively determined. Conclusions: In carriers of the minor allele of polymorphism rs2736990, the risk of MetS increases 1.3 times, regardless of age and gender [odds ratio (95% confidence interval) = 1.36 (1.01-1.82), P < 0.05], the inheritance model is log-additive.
Collapse
Affiliation(s)
- Ainur Sibagatova
- Department of Science and Gerontology, Medical Centre Hospital of President's Affairs Administration of the Republic of Kazakhstan, Astana, Republic of Kazakhstan
- Asfendiyarov Kazakh National Medical University, Almaty, Republic of Kazakhstan
| | - Valeriy Benberin
- Department of Science and Gerontology, Medical Centre Hospital of President's Affairs Administration of the Republic of Kazakhstan, Astana, Republic of Kazakhstan
- Asfendiyarov Kazakh National Medical University, Almaty, Republic of Kazakhstan
| | - Kamshat Akhmetova
- Department of Science and Gerontology, Medical Centre Hospital of President's Affairs Administration of the Republic of Kazakhstan, Astana, Republic of Kazakhstan
- Asfendiyarov Kazakh National Medical University, Almaty, Republic of Kazakhstan
| | - Dmitriy Babenko
- Department of Biology, Karaganda Medical University, Karaganda, Republic of Kazakhstan
| | - Raushan Karabayeva
- Medical Centre Hospital of President's Affairs Administration of the Republic of Kazakhstan, Astana, Republic of Kazakhstan
| |
Collapse
|
2
|
Wong T, Gao W, Chen G, Qiu C, He G, Ye F, Wu Z, Zeng Z, Du Y. Cryo-EM structure of orphan G protein-coupled receptor GPR21. MedComm (Beijing) 2023; 4:e205. [PMID: 36721851 PMCID: PMC9877262 DOI: 10.1002/mco2.205] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2022] [Revised: 12/13/2022] [Accepted: 12/18/2022] [Indexed: 01/27/2023] Open
Abstract
GPR21 belongs to class A orphan G protein-coupled receptor (GPCR). The endogenous ligands for human GPR21 remain unidentified. GPR21 expression is associated with developing type 2 diabetes (T2DM), a multifactorial metabolic disease caused by pancreatic β-cell dysfunction, decreasing insulin production, insulin resistance, and obesity. Animal studies suggested that GPR21 is a potential therapeutic target for T2DM treatment. The underlying mechanisms leading to GPR21 self-activation remain unknown. In our co-expression analysis, we noted that GPR21 could also form a stable complex with an unreported Gα protein subtype, Gαs. To gain further insights into the structural mechanisms of GPR21 activation, we employed cryo-electron microscopy (cryo-EM) and single-particle analysis to resolve the high-resolution structure of GPR21-Gαs complexes. The clear electron density map of the GPR21-Gαs provided direct evidence that GPR21 could couple to Gαs protein at physiological conditions. Thus, GPR21 might mediate previously unexplored pathways in normal or pathological conditions, which warrants further investigation. Structure-guided mutagenesis and biochemical analysis revealed that extracellular loop 2 (ECL2) of GPR21 is essential for the receptor transducing intracellular signal via cAMP. Together, the new structure data reveal a novel signaling cascade of human GPR21 mediated by ECL2 and provide fundamental information for future structure-based drug development.
Collapse
Affiliation(s)
- Thian‐Sze Wong
- Kobilka Institute of Innovative Drug Discovery, Shenzhen Key Laboratory of Steroid Drug, Discovery and Development, School of Medicinethe Chinese University of Hong KongShenzhenGuangdongChina,School of MedicineTsinghua UniversityBeijingChina
| | - Wei Gao
- Kobilka Institute of Innovative Drug Discovery, Shenzhen Key Laboratory of Steroid Drug, Discovery and Development, School of Medicinethe Chinese University of Hong KongShenzhenGuangdongChina,Innovation Center for AI and Drug DiscoveryEast China Normal UniversityShanghaiChina
| | - Geng Chen
- Kobilka Institute of Innovative Drug Discovery, Shenzhen Key Laboratory of Steroid Drug, Discovery and Development, School of Medicinethe Chinese University of Hong KongShenzhenGuangdongChina
| | - Chen Qiu
- Kobilka Institute of Innovative Drug Discovery, Shenzhen Key Laboratory of Steroid Drug, Discovery and Development, School of Medicinethe Chinese University of Hong KongShenzhenGuangdongChina
| | - Guodong He
- School of MedicineTsinghua UniversityBeijingChina
| | - Fang Ye
- Kobilka Institute of Innovative Drug Discovery, Shenzhen Key Laboratory of Steroid Drug, Discovery and Development, School of Medicinethe Chinese University of Hong KongShenzhenGuangdongChina
| | - Zhangsong Wu
- Kobilka Institute of Innovative Drug Discovery, Shenzhen Key Laboratory of Steroid Drug, Discovery and Development, School of Medicinethe Chinese University of Hong KongShenzhenGuangdongChina
| | - Zicheng Zeng
- Kobilka Institute of Innovative Drug Discovery, Shenzhen Key Laboratory of Steroid Drug, Discovery and Development, School of Medicinethe Chinese University of Hong KongShenzhenGuangdongChina
| | - Yang Du
- Kobilka Institute of Innovative Drug Discovery, Shenzhen Key Laboratory of Steroid Drug, Discovery and Development, School of Medicinethe Chinese University of Hong KongShenzhenGuangdongChina
| |
Collapse
|
3
|
Cryo-EM structures of orphan GPR21 signaling complexes. Nat Commun 2023; 14:216. [PMID: 36639690 PMCID: PMC9839698 DOI: 10.1038/s41467-023-35882-w] [Citation(s) in RCA: 8] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2022] [Accepted: 01/05/2023] [Indexed: 01/15/2023] Open
Abstract
GPR21 is a class-A orphan G protein-coupled receptor (GPCR) and a potential therapeutic target for type 2 diabetes and other metabolic disorders. This receptor shows high basal activity in coupling to multiple G proteins in the absence of any known endogenous agonist or synthetic ligand. Here, we present the structures of ligand-free human GPR21 bound to heterotrimeric miniGs and miniG15 proteins, respectively. We identified an agonist-like motif in extracellular loop 2 (ECL2) that occupies the orthosteric pocket and promotes receptor activation. A side pocket that may be employed as a new ligand binding site was also uncovered. Remarkably, G protein binding is accommodated by a flexible cytoplasmic portion of transmembrane helix 6 (TM6) which adopts little or undetectable outward movement. These findings will enable the design of modulators for GPR21 for understanding its signal transduction and exploring opportunity for deorphanization.
Collapse
|
4
|
Links between Metabolic Syndrome and Hypertension: The Relationship with the Current Antidiabetic Drugs. Metabolites 2023; 13:metabo13010087. [PMID: 36677012 PMCID: PMC9863091 DOI: 10.3390/metabo13010087] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2022] [Revised: 12/23/2022] [Accepted: 01/03/2023] [Indexed: 01/06/2023] Open
Abstract
Hypertension poses a significant burden in the general population, being responsible for increasing cardiovascular morbidity and mortality, leading to adverse outcomes. Moreover, the association of hypertension with dyslipidaemia, obesity, and insulin resistance, also known as metabolic syndrome, further increases the overall cardiovascular risk of an individual. The complex pathophysiological overlap between the components of the metabolic syndrome may in part explain how novel antidiabetic drugs express pleiotropic effects. Taking into consideration that a significant proportion of patients do not achieve target blood pressure values or glucose levels, more efforts need to be undertaken to increase awareness among patients and physicians. Novel drugs, such as incretin-based therapies and renal glucose reuptake inhibitors, show promising results in decreasing cardiovascular events in patients with metabolic syndrome. The effects of sodium-glucose co-transporter-2 inhibitors are expressed at different levels, including renoprotection through glucosuria, natriuresis and decreased intraglomerular pressure, metabolic effects such as enhanced insulin sensitivity, cardiac protection through decreased myocardial oxidative stress and, to a lesser extent, decreased blood pressure values. These pleiotropic effects are also observed after treatment with glucagon-like peptide-1 receptor agonists, positively influencing the cardiovascular outcomes of patients with metabolic syndrome. The initial combination of the two classes may be the best choice in patients with type 2 diabetes mellitus and multiple cardiovascular risk factors because of their complementary mechanisms of action. In addition, the novel mineralocorticoid receptor antagonists show significant cardio-renal benefits, as well as anti-inflammatory and anti-fibrotic effects. Overall, the key to better control of hypertension in patients with metabolic syndrome is to consider targeting multiple pathogenic mechanisms, using a combination of the different therapeutic agents, as well as drastic lifestyle changes. This article will briefly summarize the association of hypertension with metabolic syndrome, as well as take into account the influence of antidiabetic drugs on blood pressure control.
Collapse
|
5
|
Gutiérrez-Rojas RA, Aguayo-Cerón KA, Vargas-De-León C, Cabrera-Becerra SE, Almanza-Pérez JC, Huang F, Villafaña S, Romero-Nava R. Glycine Effect on the Expression Profile of Orphan Receptors GPR21, GPR26, GPR39, GPR82 and GPR6 in a Model of Inflammation in 3T3-L1 Cells. Life (Basel) 2022; 12:1687. [PMID: 36362842 PMCID: PMC9696036 DOI: 10.3390/life12111687] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2022] [Revised: 10/19/2022] [Accepted: 10/21/2022] [Indexed: 07/30/2023] Open
Abstract
BACKGROUND Chronic or low-grade inflammation is a process where various immune cells are recruited from the periphery into adipose tissue. This event gives rise to localised inflammation, in addition to having a close interaction with cardiometabolic pathologies where the mediation of orphan receptors is observed. The aim of this study was to analyse the participation of the orphan receptors GPR21, GPR39, GPR82 and GPR6 in a chronic inflammatory process in 3T3-L1 cells. The 3T3-L1 cells were stimulated with TNF-α (5 ng/mL) for 60 min as an inflammatory model. Gene expression was measured by RT-qPCR. RESULTS We showed that the inflammatory stimulus of TNF-α in adipocytes decreased the expression of the orphan receptors GPR21, GPR26, GPR39, GPR82 and GPR6, which are related to low-grade inflammation. CONCLUSIONS Our results suggest that GPR21 and GPR82 are modulated by glycine, it shows a possible protective role in the presence of an inflammatory environment in adipocytes, and they could be a therapeutic target to decrease the inflammation in some diseases related to low-grade inflammation such as diabetes, obesity and metabolic syndrome.
Collapse
Affiliation(s)
| | - Karla Aidee Aguayo-Cerón
- Laboratorio de Señalización Intracelular, Sección de Estudios de Posgrado, Escuela Superior de Medicina del Instituto Politécnico Nacional, Ciudad de México 11340, Mexico
| | - Cruz Vargas-De-León
- Laboratorio de Señalización Intracelular, Sección de Estudios de Posgrado, Escuela Superior de Medicina del Instituto Politécnico Nacional, Ciudad de México 11340, Mexico
- División de Investigación, Hospital Juárez de México, Ciudad de México 07760, Mexico
| | - Sandra Edith Cabrera-Becerra
- Laboratorio de Señalización Intracelular, Sección de Estudios de Posgrado, Escuela Superior de Medicina del Instituto Politécnico Nacional, Ciudad de México 11340, Mexico
| | - Julio Cesar Almanza-Pérez
- Laboratorio de Farmacología, Departamento de Ciencias de la Salud, DCBS, Universidad Autónoma Metropolitana-Iztapalapa (UAM-I), Ciudad de México 09340, Mexico
| | - Fengyang Huang
- Laboratorio de Investigación en Farmacología, Hospital Infantil de México Federico Gómez (HIMFG), Ciudad de México 06720, Mexico
| | - Santiago Villafaña
- Laboratorio de Señalización Intracelular, Sección de Estudios de Posgrado, Escuela Superior de Medicina del Instituto Politécnico Nacional, Ciudad de México 11340, Mexico
| | - Rodrigo Romero-Nava
- Laboratorio de Señalización Intracelular, Sección de Estudios de Posgrado, Escuela Superior de Medicina del Instituto Politécnico Nacional, Ciudad de México 11340, Mexico
| |
Collapse
|
6
|
G protein–coupled receptor 21 in macrophages: An in vitro study. Eur J Pharmacol 2022; 926:175018. [DOI: 10.1016/j.ejphar.2022.175018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2021] [Revised: 04/27/2022] [Accepted: 05/04/2022] [Indexed: 11/20/2022]
|
7
|
Gutiérrez-Ruiz JR, Villafaña S, Ruiz-Hernández A, Viruette-Pontigo D, Menchaca-Cervantes C, Aguayo-Cerón KA, Huang F, Hong E, Romero-Nava R. Expression profiles of GPR21, GPR39, GPR135, and GPR153 orphan receptors in different cancers. NUCLEOSIDES, NUCLEOTIDES & NUCLEIC ACIDS 2022; 41:123-136. [PMID: 35021931 DOI: 10.1080/15257770.2021.2002892] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/22/2020] [Revised: 11/01/2021] [Accepted: 11/02/2021] [Indexed: 05/28/2023]
Abstract
Orphan receptors have unknown endogenous ligands, are expressed in different tissues, and participate in various diseases such as diabetes, hypertension and cancer. We studied the expression profiles of GPR21, GPR39, GPR135 and GPR153 orphan receptors in several tumour tissues. Cervical, breast, skin, prostate, and astrocytoma tissues were analysed for orphan receptor gene expression using Real time PCR analysis. GPR39 is over-expressed in cervical and prostate cancer tissues, and GPR21 and GPR135 receptors are significantly decreased in cervical, breast, skin, prostate, and astrocytoma tissues, when compared with healthy human fibroblasts. In conclusion, GPR21 and GPR135 receptor gene expression is reduced in cancerous tissues. GPR39 may have a role in the development and evolution of cervical and prostate cancer. These data suggest these receptors may be alternative molecules for new diagnostic approaches, and the design of novel therapeutics against oncological pathologies.
Collapse
Affiliation(s)
- Juan René Gutiérrez-Ruiz
- Escuela Superior de Medicina del Instituto Politécnico Nacional, Sección de Estudios de Posgrado e Investigación, Ciudad de México, México
- Secretaria de Salud del estado de Chiapas, Tuxtla Gutiérrez, Chiapas, México
| | - Santiago Villafaña
- Escuela Superior de Medicina del Instituto Politécnico Nacional, Sección de Estudios de Posgrado e Investigación, Ciudad de México, México
| | - Armando Ruiz-Hernández
- Departamento de Farmacología, Facultad de Medicina, Universidad Autónoma de Baja California, Mexicali, Baja California, México
| | | | | | - Karla Aidee Aguayo-Cerón
- Escuela Superior de Medicina del Instituto Politécnico Nacional, Sección de Estudios de Posgrado e Investigación, Ciudad de México, México
| | - Fengyang Huang
- Departamento de Investigación en Farmacología, Hospital Infantil de México Federico Gómez, Ciudad de México, México
| | - Enrique Hong
- Departamento de Farmacobiología sede Sur, CINVESTAV, Ciudad de México, México
| | - Rodrigo Romero-Nava
- Escuela Superior de Medicina del Instituto Politécnico Nacional, Sección de Estudios de Posgrado e Investigación, Ciudad de México, México
| |
Collapse
|
8
|
Metabolic Syndrome: Updates on Pathophysiology and Management in 2021. Int J Mol Sci 2022; 23:ijms23020786. [PMID: 35054972 PMCID: PMC8775991 DOI: 10.3390/ijms23020786] [Citation(s) in RCA: 333] [Impact Index Per Article: 166.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2021] [Revised: 12/22/2021] [Accepted: 12/23/2021] [Indexed: 12/18/2022] Open
Abstract
Metabolic syndrome (MetS) forms a cluster of metabolic dysregulations including insulin resistance, atherogenic dyslipidemia, central obesity, and hypertension. The pathogenesis of MetS encompasses multiple genetic and acquired entities that fall under the umbrella of insulin resistance and chronic low-grade inflammation. If left untreated, MetS is significantly associated with an increased risk of developing diabetes and cardiovascular diseases (CVDs). Given that CVDs constitute by far the leading cause of morbidity and mortality worldwide, it has become essential to investigate the role played by MetS in this context to reduce the heavy burden of the disease. As such, and while MetS relatively constitutes a novel clinical entity, the extent of research about the disease has been exponentially growing in the past few decades. However, many aspects of this clinical entity are still not completely understood, and many questions remain unanswered to date. In this review, we provide a historical background and highlight the epidemiology of MetS. We also discuss the current and latest knowledge about the histopathology and pathophysiology of the disease. Finally, we summarize the most recent updates about the management and the prevention of this clinical syndrome.
Collapse
|
9
|
Kinsella GK, Cannito S, Bordano V, Stephens JC, Rosa AC, Miglio G, Guaschino V, Iannaccone V, Findlay JBC, Benetti E. GPR21 Inhibition Increases Glucose-Uptake in HepG2 Cells. Int J Mol Sci 2021; 22:ijms221910784. [PMID: 34639123 PMCID: PMC8509304 DOI: 10.3390/ijms221910784] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2021] [Revised: 09/24/2021] [Accepted: 09/29/2021] [Indexed: 02/08/2023] Open
Abstract
GPR21 is a constitutively active, orphan, G-protein-coupled receptor, with in vivo studies suggesting its involvement in the modulation of insulin sensitivity. However, its precise contribution is not fully understood. As the liver is both a major target of insulin signalling and critically involved in glucose metabolism, the aim of this study was to examine the role of GPR21 in the regulation of glucose uptake and production in human hepatocytes. In particular, HepG2 cells, which express GPR21, were adopted as cellular models. Compared with untreated cells, a significant increase in glucose uptake was measured in cells treated with siRNA to downregulate GPR21 expression or with the GPR21-inverse agonist, GRA2. Consistently, a significantly higher membrane translocation of GLUT-2 was measured under these conditions. These effects were accompanied by an increased ratio of phAKT(Ser473)/tot-AKT and phGSK-3β(Ser9)/tot-GSK-3β, thus indicating a marked activation of the insulin signalling pathway. Moreover, a significant reduction in ERK activation was observed with GPR21 inhibition. Collectively, these results indicate that GPR21 mediates the negative effects on glucose uptake by the liver cells. In addition, they suggest that the pharmacological inhibition of GPR21 could be a novel strategy to improve glucose homeostasis and counteract hepatic insulin resistance.
Collapse
Affiliation(s)
- Gemma K. Kinsella
- School of Food Sciences and Environmental Health, Technological University Dublin, Grangegorman, D07 ADY7 Dublin, Ireland;
| | - Stefania Cannito
- Department of Clinical and Biological Sciences, University of Turin, 10125 Turin, Italy;
| | - Valentina Bordano
- Dipartimento di Scienza e Tecnologia del Farmaco, University of Turin, Via Pietro Giuria 9, 10125 Turin, Italy; (V.B.); (A.C.R.); (G.M.); (V.G.); (V.I.)
| | - John C. Stephens
- Department of Chemistry, Maynooth University, Maynooth, Co. Kildare, Ireland;
- Kathleen Lonsdale Institute for Human Health Research, Maynooth University, Maynooth, Co. Kildare, Ireland
| | - Arianna C. Rosa
- Dipartimento di Scienza e Tecnologia del Farmaco, University of Turin, Via Pietro Giuria 9, 10125 Turin, Italy; (V.B.); (A.C.R.); (G.M.); (V.G.); (V.I.)
| | - Gianluca Miglio
- Dipartimento di Scienza e Tecnologia del Farmaco, University of Turin, Via Pietro Giuria 9, 10125 Turin, Italy; (V.B.); (A.C.R.); (G.M.); (V.G.); (V.I.)
| | - Valeria Guaschino
- Dipartimento di Scienza e Tecnologia del Farmaco, University of Turin, Via Pietro Giuria 9, 10125 Turin, Italy; (V.B.); (A.C.R.); (G.M.); (V.G.); (V.I.)
| | - Valeria Iannaccone
- Dipartimento di Scienza e Tecnologia del Farmaco, University of Turin, Via Pietro Giuria 9, 10125 Turin, Italy; (V.B.); (A.C.R.); (G.M.); (V.G.); (V.I.)
| | - John B. C. Findlay
- Department of Biology, Maynooth University, Maynooth, Co. Kildare, Ireland;
- School of Biomedical Sciences, University of Leeds, LS2 9JT Leeds, UK
| | - Elisa Benetti
- Dipartimento di Scienza e Tecnologia del Farmaco, University of Turin, Via Pietro Giuria 9, 10125 Turin, Italy; (V.B.); (A.C.R.); (G.M.); (V.G.); (V.I.)
- Correspondence: ; Tel.: +39-0116707137
| |
Collapse
|